FDA OKs Remdesivir for Non-Hospitalized Patients at High Risk for COVID-19

 Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo --

-- NIH Guidelines Recommend Veklury for the Treatment of Non-Hospitalized Patients at High Risk --

-- FDA Expands Pediatric Emergency Use Authorization (EUA) to Include Treatment of Non-Hospitalized Pediatric Patients at High Risk --

https://www.biospace.com/article/releases/fda-approves-veklury-remdesivir-for-the-treatment-of-non-hospitalized-patients-at-high-risk-for-covid-19-disease-progression/